- Home
- BIIB vs OKTA Comparison
BIIB vs OKTA Comparison
Compare BIIB & OKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- OKTA
- Stock Information
- Founded
- BIIB 1978
- OKTA 2009
- Country
- BIIB United States
- OKTA United States
- Employees
- BIIB N/A
- OKTA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- OKTA Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- OKTA Technology
- Exchange
- BIIB Nasdaq
- OKTA Nasdaq
- Market Cap
- BIIB 18.7B
- OKTA 15.8B
- IPO Year
- BIIB 1991
- OKTA 2017
- Fundamental
- Price
- BIIB $155.51
- OKTA $85.21
- Analyst Decision
- BIIB Buy
- OKTA Buy
- Analyst Count
- BIIB 24
- OKTA 40
- Target Price
- BIIB $174.62
- OKTA $121.95
- AVG Volume (30 Days)
- BIIB 1.6M
- OKTA 1.8M
- Earning Date
- BIIB 10-30-2025
- OKTA 12-02-2025
- Dividend Yield
- BIIB N/A
- OKTA N/A
- EPS Growth
- BIIB N/A
- OKTA N/A
- EPS
- BIIB 10.97
- OKTA 0.84
- Revenue
- BIIB $10,065,900,000.00
- OKTA $2,763,000,000.00
- Revenue This Year
- BIIB $2.97
- OKTA $12.72
- Revenue Next Year
- BIIB N/A
- OKTA $9.38
- P/E Ratio
- BIIB $14.17
- OKTA $101.88
- Revenue Growth
- BIIB 4.77
- OKTA 12.68
- 52 Week Low
- BIIB $110.04
- OKTA $71.84
- 52 Week High
- BIIB $176.95
- OKTA $127.57
- Technical
- Relative Strength Index (RSI)
- BIIB 59.29
- OKTA 38.29
- Support Level
- BIIB $148.90
- OKTA $86.91
- Resistance Level
- BIIB $157.79
- OKTA $92.50
- Average True Range (ATR)
- BIIB 4.78
- OKTA 2.30
- MACD
- BIIB 0.43
- OKTA -0.29
- Stochastic Oscillator
- BIIB 82.77
- OKTA 17.32
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About OKTA Okta Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.